420
Participants
Start Date
August 31, 2012
Primary Completion Date
December 31, 2013
Study Completion Date
January 31, 2014
Mavrilimumab 30 mg
Mavrilimumab (CAM-3001) 30 mg injection subcutaneously every 2 weeks for 24 weeks
Mavrilimumab 100 mg
Mavrilimumab (CAM-3001) 100 mg injection subcutaneously every 2 weeks for 24 weeks.
Mavrilimumab 150 mg
Mavrilimumab (CAM-3001) 150 mg injection subcutaneously every 2 weeks for 24 weeks.
Placebo
Placebo matched to mavrilimumab (CAM-3001) injection subcutaneously every 2 weeks for 24 weeks.
Research Site, Ciudad Autonoma de Buenos Aire
Research Site, Rosario
Research Site, San Miguel de Tucumán
Research Site, Plovdiv
Research Site, Sofia
Research Site, Santiago
Research Site, Viña del Mar
Research Site, Barranquilla
Research Site, Bogotá
Research Site, Bruntál
Research Site, Jihlava
Research Site, Ostrava - Trebovice
Research Site, Prague
Research Site, Zlín
Research Site, Tallinn
Research Site, Cologne
Research Site, Hildesheim
Research Site, Magdeburg
Research Site, Budapest
Research Site, Debrecen
Research Site, Gdynia
Research Site, Grodzisk Mazowiecki
Research Site, Katowice
Research Site, Krakow
Research Site, Warsaw
Research Site, Wroclaw
Research Site, Barnaul
Research Site, Kazan'
Research Site, Moscow
Research Site, Novosibirsk
Research Site, Saint Petersburg
Research Site, Yaroslavl
Research Site, Belgrade
Research Site, Niška Banja
Research Site, Durban
Research Site, Barcelona
Research Site, Santiago de Compostela
Research Site, Donetsk
Research Site, Kharkiv
Research Site, Kiev
Research Site, Lutsk
Research Site, Vinnytsia
Lead Sponsor
Collaborators (1)
MedImmune Ltd
INDUSTRY
MedImmune LLC
INDUSTRY